Systemic

Martinrea International Inc. Publishes 2023 Sustainability Report

Retrieved on: 
Friday, March 1, 2024

VAUGHAN, Ontario, March 01, 2024 (GLOBE NEWSWIRE) -- Martinrea International Inc. (TSX: MRE), a diversified and global automotive supplier engaged in the design, development, and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems, announced the release of its 2023 Sustainability Report.

Key Points: 
  • VAUGHAN, Ontario, March 01, 2024 (GLOBE NEWSWIRE) -- Martinrea International Inc. (TSX: MRE), a diversified and global automotive supplier engaged in the design, development, and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems, announced the release of its 2023 Sustainability Report.
  • This report showcases Martinrea’s commitment to Environmental, Social, and Governance (ESG) by featuring sustainability achievements over the past year and our strategy for further improvement.
  • “By utilizing our expertise in product development and lightweighting technologies, we are committed to advancing our sustainability initiatives; helping to decrease global carbon emissions and remain ahead of market changes.”
    “Our sustainability and success also comes down to culture, as emphasized in our 2023 Sustainability Report,” said Rob Wildeboer, Executive Chairman.
  • To view or download Martinrea’s 2023 Sustainability Report, visit: www.martinrea.com/sustainability/

Accurate Identification of Sepsis using SeptiCyte® RAPID and Comparison with other Biomarkers Presented at Society of Critical Care Medicine (SCCM) Critical Care Congress 2024

Retrieved on: 
Monday, January 22, 2024

SEATTLE and BRISBANE, Australia, Jan. 22, 2024 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced  that data validating the use of SeptiCyte® RAPID in differentiating sepsis from systemic inflammatory response syndrome (SIRS) was selected for presentation on Sunday, January 21, during the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress in Phoenix, Arizona, January 21 to 23, 2024.

Key Points: 
  • Immunexpress Chief Medical Officer Dr. Roy Davis presented the poster entitled, "Accurate Sepsis Identification Using SeptiCyte® RAPID & Other Biomarkers of Systemic Inflammation" in a Research Snapshot theatre and fielded questions afterward in a Q&A discussion.
  • "The data demonstrate that no combination of biomarkers outperformed SeptiScore alone, or models including SeptiScore, at identifying sepsis," said Dr. Roy Davis, MD, PhD, MHA, Chief Medical Officer of Immunexpress.
  • "This is clinically meaningful as it demonstrates that SeptiCyte RAPID can be used to help diagnose sepsis more accurately than current sepsis diagnostic tools or clinical variables.
  • SeptiCyte RAPID isn't intended to be used as a standalone test, but in this study adding other biomarkers to SeptiScore didn't appreciably increase the diagnostic certainty of differentiating sepsis from SIRS."

United Renewables Embraces COP28 Insights to Forge a Progressive Path in 2024

Retrieved on: 
Tuesday, January 9, 2024

DOUGLAS, Isle of Man, Jan. 09, 2024 (GLOBE NEWSWIRE) -- In the wake of the influential COP28 Debrief Breakfast, United Renewables is poised to announce its ambitious plans for 2024, marking a significant step forward in the renewable energy sector. This strategic move, influenced by the outcomes of COP28, positions the company to address the challenges and seize the opportunities in a rapidly evolving energy landscape.

Key Points: 
  • United Renewables played a pivotal role in these conversations, shaping a forward-thinking strategy that responds to the global need for sustainable energy solutions.
  • United Renewables' Vision for 2024:
    Ramping Up Renewable Energy: Aligned with the global goal to triple renewable energy by 2030, United Renewables is expanding its portfolio of green energy projects.
  • Setting New Standards: As a leader in renewable energy, United Renewables is committed to raising the bar for sustainability and innovation.
  • United Renewables invites everyone to be part of this transformative journey towards a sustainable 2024.

The Josh Bersin Company Introduces Systemic HR™, a Global Initiative to Redefine the Role of Human Resources in Business

Retrieved on: 
Tuesday, December 5, 2023

The Systemic HR Initiative, including a new study, The Definitive Guide to Human Resources: Systemic HR, from The Josh Bersin Company, is designed to help CHROs address these issues.

Key Points: 
  • The Systemic HR Initiative, including a new study, The Definitive Guide to Human Resources: Systemic HR, from The Josh Bersin Company, is designed to help CHROs address these issues.
  • "We believe adoption of the Systemic HR Initiative moves HR from a service delivery function to a proactive, solution-based consulting and advisory role."
  • Systemic HR research deliverables include a comprehensive research study, an organizational maturity model, Systemic HR Framework, specific action steps to move to Systemic HR, and a series of in-depth case studies describing the journey towards Systemic HR.
  • The Josh Bersin Company will also be launching a Systemic HR Awards program, starting at the company's annual executive conference, Irresistible 2024, to celebrate companies that embrace and implement the principles and practices of Systemic HR.

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

Retrieved on: 
Thursday, November 23, 2023

Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a.

Key Points: 
  • Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a.
  • The results underscore the novel mechanism of action, demonstrating the ability of PMC-403 to reduce vascular leakage associated with ISCLS in the preclinical models.
  • In February 2023, the US FDA granted Orphan Drug Designation (ODD) for PMC-403 for the treatment of Systemic Capillary Leak Syndrome.
  • Dr. Kirk Druey's team shared enthusiasm for the potential breakthrough, underscoring their strong determination to advance into clinical trial.

DENSO's Christina Khim Earns Runner Up at the CADIA Impact Awards in Systemic Change Category

Retrieved on: 
Thursday, November 9, 2023

SOUTHFIELD, Mich., Nov. 9, 2023 /PRNewswire/ -- DENSO, a leading mobility supplier, today announced that CADIA has recognized Christina Khim as Runner Up of the 2023 CADIA Impact Awards in the category of Systemic Change, Individual. Khim is an advanced human resources (HR) business partner at DENSO's thermal manufacturing facility in Battle Creek, Michigan, who works tirelessly to bridge cultural divides and support employees of diverse backgrounds. 

Key Points: 
  • Khim honored for contributions to workplace diversity, equity and inclusion
    SOUTHFIELD, Mich., Nov. 9, 2023 /PRNewswire/ -- DENSO , a leading mobility supplier, today announced that CADIA has recognized Christina Khim as Runner Up of the 2023 CADIA Impact Awards in the category of Systemic Change, Individual.
  • "I'm honored to be recognized at this year's CADIA Impact Awards," Khim said.
  • The Systemic Change category of the CADIA Impact Awards highlights individuals and teams who are determined to break down systemic bias and address organizational barriers to inclusion and equity in the workplace.
  • "We are pleased to celebrate Christina's ability to spark systemic change and make a positive impact," said Cheryl Thompson, founder and CEO of CADIA.

Cardiometabolic Health Congress Becomes First Organization to Offer Certification in Cardiometabolic Health

Retrieved on: 
Thursday, November 9, 2023

Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now have the opportunity to sit for the Certified Cardiometabolic Health Professional (CCHP) examination.

Key Points: 
  • Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now have the opportunity to sit for the Certified Cardiometabolic Health Professional (CCHP) examination.
  • Regarding the certification announcement, Dr. Eckel said, "I cannot overstate the tremendous implications of having a dedicated certification on the entire field of cardiometabolic health.
  • The Foundations of Cardiometabolic Health Certificate Course is currently open for enrollment to physicians, nurses, residents, fellows, and any other health professional interested in furthering their knowledge in the core principles of cardiometabolic health.
  • Cardiometabolic Health Congress (CMHC) is a single point of access for breakthrough research, comprehensive education, and practical clinical strategies surrounding cardiometabolic health.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
Wednesday, November 1, 2023

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.

Kernal Biologics to Present at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023

CAMBRIDGE, Mass., Oct. 31, 2023 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced it is presenting a poster at the Society for Immunotherapy of Cancer 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA.

Key Points: 
  • KR-336 Data Support Use of Onco-selective mRNA LNPs as a Novel, Promising Modality for Systemic Immuno-oncology Applications
    CAMBRIDGE, Mass., Oct. 31, 2023 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced it is presenting a poster at the Society for Immunotherapy of Cancer 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA.
  • The poster presentation features preclinical insights into KR-336, an onco-selective mRNA LNP therapeutic that Kernal Bio has rationally designed using their mRNA2.0 platform to be selectively translated into therapeutic protein within the tumor microenvironment.
  • "At SITC, we look forward to reporting the outcome of in vivo proof-of-concept studies for systemic mRNA LNP administration, which resulted in robust anti-tumor effectiveness."
  • Details for the Kernal Bio presentation are as follows:
    Poster Presentation: Systemically Administered Onco-Selective mRNA LNP Achieves Tumor Regression and Improves Overall Survival, As Monotherapy
    Presenter: Matthew Strout, MD, PhD, Vice President of Business Development, Kernal Biologics

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

Retrieved on: 
Saturday, October 21, 2023

“This is the first comprehensive data set for EGFR exon 20 patients with such an exceptionally high rate of CNS disease at baseline and prior exon 20 inhibitor therapy.

Key Points: 
  • “This is the first comprehensive data set for EGFR exon 20 patients with such an exceptionally high rate of CNS disease at baseline and prior exon 20 inhibitor therapy.
  • Patients previously treated with an exon 20 targeted agent are eligible, including patients with CNS metastases that are either treated or untreated but asymptomatic.
  • As of September 26, 2023, 50 patients (21 EGFR exon 20, 24 HER2 exon 20 and 5 HER2+ patients) received ORIC-114 and were heavily pre-treated, with exceptionally high rates of prior exon 20 targeted therapies and brain metastases at baseline.
  • The Phase 1 trial will enroll patients with EGFR exon 20 insertion mutations that are EGFR exon 20 inhibitor-naïve, and additional patients who are post-amivantamab.